Review Article| Volume 41, ISSUE 1, P249-261, March 2023

Coagulopathy and Emergent Reversal of Anticoagulation


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Anesthesiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pai M.
        Chapter 129: laboratory evaluation of hemostatic and thrombotic disorders.
        in: Hoffman R. Benz E. Silberstein L. Hematology, basic principles and practice. 7th ed. Elsevier, Philadelphia2018: 1922-1931
        • Winter W.E.
        • Flax S.D.
        • Harris N.S.
        Coagulation testing in the core laboratory.
        Lab Med. 2017; 48: 295-313
        • Shore-Lesserson L.
        • Enriquez L.
        • Weitzel N.
        Chapter 19: coagulation monitoring.
        in: Kaplan J. Kaplan's cardiac anesthesia. 7th ed. Elsevier, Philadelphia2017: 698-727
        • Shen L.
        • Tabaie S.
        • Ivascu N.
        Viscoelastic testing inside and beyond the operating room.
        J Thorac Dis. 2017; 9: S299-S308
        • Jaffer I.H.
        • Weitz J.I.
        Antithrombotic drugs.
        in: Hoffman R. Benz E.J. Silberstein L.E. Hematology: basic principles and practice. 7th edition. Elsevier, Philadelphia2018: 2168-2188
        • Milling T.J.
        • Pollack C.V.
        A review of guidelines on anticoagulation reversal across different clinical scenarios––Is there a general consensus?.
        Am J Emerg Med. 2020; 38: 1890-1903
        • Goldstein J.N.
        • Refaai M.A.
        • Milling Jr., T.J.
        • et al.
        Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial.
        Lancet. 2015; 385: 2077-2087
        • Chai-Adisaksopha C.
        • Hillis C.
        • Siegal D.M.
        • et al.
        Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal: a systematic review and meta-analysis.
        Thromb Haemost. 2016; 116: 879-890
        • Frontera J.A.
        • Lewin J.J.
        • Rabinstein A.A.
        • et al.
        Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine.
        Neurocrit Care. 2015; 24: 6-46
        • Abdoellakhan R.A.
        • Khorsand N.
        • ter Avest E.
        • et al.
        Fixed versus variable dosing of prothrombin complex concentrate for bleeding complications of vitamin K antagonists––the PROPER3 randomized clinical trial.
        Ann Emerg Med. 2022; 79: 20-30
        • Royston D.
        Chapter 45: anticoagulant and antiplatelet therapy.
        in: Hemminds H.C. Egan T.D. Pharmacology and physiology for anesthesia: foundations and clinical application. 2nd edition. Elsevier, Philadelphia2019: 870-894
        • Weitz J.I.
        Chapter 95: Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease.
        in: Libby P. Bonow R.O. Mann D.L. Braunwald’s heart disease: a textbook of cardiovascular medicine. 12th edition. Elsevier, Philadelphia2022: 1766-1790
        • Siegal D.M.
        • Curnutte J.T.
        • Connolly S.J.
        • et al.
        Andexanet alfa for the reversal of factor Xa inhibitor activity.
        N Engl J Med. 2015; 373: 2413-2424
        • Zehnder J.
        • Price E.
        • Jin J.
        Controversies in heparin monitoring.
        Am J Hematol. 2012; 87: S137-S140
        • Simon E.
        • Streitz M.
        • Sessions D.
        • et al.
        Anticoagulation reversal.
        Emerg Med Clin North America. 2018; 36: 585-601
        • Connolly S.J.
        • Crowther M.
        • Eikelboom J.W.
        • et al.
        Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors.
        N Engl J Med. 2019; 380: 1326-1335
        • Wahab A.
        • Patnaik R.
        • Gurjar M.
        Use of direct oral anticoagulants in ICU patients. Part I––applied pharmacology.
        Anaesthesiol Intensive Ther. 2021; 53: 429-439
        • Chen A.
        • Stecker E.
        • Warden B.A.
        Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges.
        J Am Heart Assoc. 2020; 9: e017559
        • Tomaselli G.F.
        • Mahaffey K.W.
        • Cuker A.
        • et al.
        2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology task force on expert consensus decision pathways.
        J Am Coll Cardiol. 2017; 70: 3042-3067
        • Stevens S.M.
        • Woller S.C.
        • Baumann Kreuziger L.
        • et al.
        Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report.
        Chest. 2021; 160: e545-e608
        • Lopez-Lopez J.A.
        • Sterne J.A.C.
        • Thom H.H.Z.
        • et al.
        Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
        BMJ. 2017; 359: j5058
        • Wahab A.
        • Patnaik R.
        • Gurjar M.
        Use of direct oral anticoagulants in ICU patients. Part II- Clinical evidence.
        Anaesthesiol Intensive Ther. 2021; 53: 440-449
        • Larsen T.B.
        • Rasmussen L.H.
        • Skjoth F.
        • et al.
        Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study.
        J Am Coll Cardiol. 2013; 61: 2264-2273
        • Siegal D.M.
        • Garcia D.A.
        • Crowther M.A.
        How I treat target-specific oral anticoagulant-associated bleeding.
        Blood. 2014; 123: 1152-1158
        • Pengo V.
        • Pegoraro C.
        • Cucchini U.
        • et al.
        Worldwide management of oral anticoagulant therapy: the ISAM study.
        J Thromb Thrombolysis. 2006; 21: 73-77
        • Ding Z.
        • Kim S.
        • Dorsam R.T.
        • et al.
        Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.
        Blood. 2003; 101: 3908-3914
        • Michelson A.D.
        • Bhatt D.L.
        How I use laboratory monitoring of antiplatelet therapy.
        Blood. 2017; 130: 713-721
        • Mahla E.
        • Tantry U.S.
        • Schoerghuber M.
        • et al.
        Platelet function testing in patients on antiplatelet therapy before cardiac surgery.
        Anesthesiology. 2020; 133: 1263-1276
        • Yee J.
        • Kaide C.G.
        Emergency reversal of anticoagulation.
        West J Emerg Med. 2019; 20: 770-783
        • Bhal V.
        • Herr M.J.
        • Dixon M.
        • et al.
        Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.
        Thromb Res. 2015; 136: 1216-1223
        • Kathma S.J.
        • Wheeler J.J.
        • Bhatt D.L.
        • et al.
        Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers.
        CPT Pharmacometrics Syst Pharmacol. 2022; 11: 68-81
        • Granja T.
        • Hohenstein K.
        • Schussel P.
        • et al.
        Multi-modal characterization of the coagulopathy associated with extracorporeal membrane oxygenation.
        Crit Care Med. 2020 May; 48: e400-e408
        • Heilmann C.
        • Geisen U.
        • Beyersdorf F.
        • et al.
        Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS).
        Intensive Care Med. 2012; 38: 62-68
        • Harrington D.J.
        • Booth L.
        • Dando N.
        • et al.
        Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status.
        Int J Lab Hematol. 2013; 35: 457-459
        • Galbusera M.
        • Remuzzi G.
        • Boccardo P.
        Treatment of bleeding in dialysis patients.
        Semin Dial. 2009; 22: 279-286
        • Kornblith L.Z.
        • Moore H.B.
        • Cohen M.J.
        Trauma-induced coagulopathy: The past, present, and future.
        J Thromb Haemost. 2019; 17: 852-862
        • Shakur H.
        • Roberts I.
        • Bautista R.
        • et al.
        Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant hemorrhage (CRASH-2): a randomized, placebo-controlled trial.
        Lancet. 2010; 376: 23-32